Digel Pharmaceuticals announced that the company signed a license agreement with AstraZeneca to grant AstraZeneca the exclusive right to develop and commercialize Schwarzer worldwide. The company will receive a one-time, non-refundable down payment of $600 million from AstraZeneca, clinical development milestone payments of up to $400 million, sales milestone payments of up to $500 million, and royalties based on a tiered ratio of the highest to the lowest double digits of Schwarzer's global sales.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.